Catalyst Pharma CEO Richard Daly gives an overview of the company's three commercial products, and discusses the 'buy to build' model
- blonca9
- Sep 8
- 1 min read
Updated: Sep 9
He highlights the market penetration of FIRDAPSE, the differentiation he believes AGAMREE represents in the DMD space, and FYCOMPA. Plus, the company's financial strength.
Coverage brought to you by:












.png)




